LT4308114T - C5ar1 inhibitoriai, skirti padidėjusio jautrumo reakcijoms taksanams gydyti - Google Patents
C5ar1 inhibitoriai, skirti padidėjusio jautrumo reakcijoms taksanams gydytiInfo
- Publication number
- LT4308114T LT4308114T LTEPPCT/EP2022/057007T LTEP2022057007T LT4308114T LT 4308114 T LT4308114 T LT 4308114T LT EP2022057007 T LTEP2022057007 T LT EP2022057007T LT 4308114 T LT4308114 T LT 4308114T
- Authority
- LT
- Lithuania
- Prior art keywords
- c5ar1
- taxanes
- inhibitors
- hypersensitivity reactions
- treating hypersensitivity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21163292.2A EP4059497A1 (en) | 2021-03-17 | 2021-03-17 | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
| EP21217382 | 2021-12-23 | ||
| PCT/EP2022/057007 WO2022195017A1 (en) | 2021-03-17 | 2022-03-17 | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT4308114T true LT4308114T (lt) | 2026-03-25 |
Family
ID=81307212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2022/057007T LT4308114T (lt) | 2021-03-17 | 2022-03-17 | C5ar1 inhibitoriai, skirti padidėjusio jautrumo reakcijoms taksanams gydyti |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240180888A1 (https=) |
| EP (1) | EP4308114B1 (https=) |
| JP (1) | JP2024512472A (https=) |
| BR (1) | BR112023018826A2 (https=) |
| CA (1) | CA3212816A1 (https=) |
| DK (1) | DK4308114T3 (https=) |
| FI (1) | FI4308114T3 (https=) |
| HR (1) | HRP20260351T1 (https=) |
| IL (1) | IL305727A (https=) |
| LT (1) | LT4308114T (https=) |
| WO (1) | WO2022195017A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025193888A1 (en) * | 2024-03-14 | 2025-09-18 | Vanqua Bio, Inc. | Pyridazinone c5ar1 antagonists and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1261275A (zh) * | 1997-05-27 | 2000-07-26 | 巴克·诺顿药物有限公司 | 给予病人口服紫杉烷类药物的方法和组合物 |
| CA2298475A1 (en) * | 1997-10-31 | 1999-05-14 | Walter Reed Army Institute Of Research | Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules |
| JP2003512443A (ja) * | 1999-10-27 | 2003-04-02 | ベーカー ノートン ファーマシューティカルズ インコーポレイテッド | タキサンをヒト患者に経口投与するための方法及び組成物 |
| ES2597843T3 (es) | 2005-11-24 | 2017-01-23 | Dompé Farmaceutici S.P.A. | Derivados de (R)-arilalquilamino y composiciones farmacéuticas que los contienen |
| EP3498269A1 (en) * | 2017-12-12 | 2019-06-19 | Dompé farmaceutici S.p.A. | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain |
-
2022
- 2022-03-17 BR BR112023018826A patent/BR112023018826A2/pt unknown
- 2022-03-17 WO PCT/EP2022/057007 patent/WO2022195017A1/en not_active Ceased
- 2022-03-17 FI FIEP22716203.9T patent/FI4308114T3/fi active
- 2022-03-17 US US18/282,357 patent/US20240180888A1/en active Pending
- 2022-03-17 CA CA3212816A patent/CA3212816A1/en active Pending
- 2022-03-17 LT LTEPPCT/EP2022/057007T patent/LT4308114T/lt unknown
- 2022-03-17 IL IL305727A patent/IL305727A/en unknown
- 2022-03-17 HR HRP20260351TT patent/HRP20260351T1/hr unknown
- 2022-03-17 EP EP22716203.9A patent/EP4308114B1/en active Active
- 2022-03-17 DK DK22716203.9T patent/DK4308114T3/da active
- 2022-03-17 JP JP2023556979A patent/JP2024512472A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240180888A1 (en) | 2024-06-06 |
| DK4308114T3 (da) | 2026-03-23 |
| FI4308114T3 (fi) | 2026-03-25 |
| BR112023018826A2 (pt) | 2024-03-12 |
| WO2022195017A1 (en) | 2022-09-22 |
| HRP20260351T1 (hr) | 2026-04-24 |
| EP4308114B1 (en) | 2026-02-11 |
| JP2024512472A (ja) | 2024-03-19 |
| CA3212816A1 (en) | 2022-09-22 |
| EP4308114A1 (en) | 2024-01-24 |
| IL305727A (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202011110PA (en) | Methods of treating skin cancer by administering a pd-1 inhibitor | |
| SG11201706918YA (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| IL259164A (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201710625SA (en) | Mixture for treating fertilisers containing urea | |
| BR112014029404A2 (pt) | compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção | |
| EP2717870A4 (en) | COMPOUNDS AND COMPOSITIONS FOR STABILIZING THE HYPOXIA-INDUCIBLE FACTOR-2 ALPHA AS METHOD FOR THE TREATMENT OF CANCER | |
| PH12014502513A1 (en) | Nampt inhibitors | |
| EP2526118A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF EGG CANCER | |
| EP3107626A4 (en) | Inhibitors of leukotriene-mediated activity for treating side effects of statin therapy | |
| ZA202206163B (en) | Methods of treating coronavirus | |
| PL2920133T3 (pl) | Kompozycja do zaprawiania korzeni roślin | |
| IL285050A (en) | Administering PD-1 inhibitors for the treatment of skin cancer | |
| IL239768A0 (en) | T-type calcium channel inhibitors for cancer treatment | |
| SG11202105531XA (en) | Methods for treating cancer resistant to cdk4/6 inhibitors | |
| IL274198A (en) | Use of Nox inhibitors to treat cancer | |
| IL287210A (en) | Preparations for the treatment of tumors | |
| IL316829A (en) | Menin-MLL inhibitors for cancer treatment | |
| LT4308114T (lt) | C5ar1 inhibitoriai, skirti padidėjusio jautrumo reakcijoms taksanams gydyti | |
| MX2014013758A (es) | Derivados de tiazolcarboxamida para usarse como inhibidores de nampt. | |
| IL289811A (en) | A method for treating cancer | |
| IL289201A (en) | Compounds for the treatment of cancer | |
| IL288665A (en) | Methods for treating cancer using prmt5 inhibitors | |
| ZA202106581B (en) | Use of topical braf inhibitor compositions for treatment of radiation dermatitis | |
| IL288003A (en) | Cancer treatment methods using chk1 inhibitors | |
| HK40097618A (en) | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |